BMS 690514

Drug Profile

BMS 690514

Alternative Names: BMS-690514

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 26 Oct 2011 Safety and pharmacokinetic data from two phase I trials in healthy volunteers released Bristol-Myers Squibb ,
  • 26 Oct 2011 Bristol-Myers Squibb completes a phase I pharmacokinetic trial in healthy volunteers in Switzerland
  • 18 Jul 2011 Bristol-Myers Squibb completes a phase II trial for Non-small cell lung cancer (second-line therapy or greater) in Japan (NCT01167244)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top